News | August 23, 2024
Sun Pharma introduces STARIZO in India for skin infections
Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India
Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India
Patni brings over 25 years of distinguished experience in the pharmaceutical industry
Sigachi's entry into the coatings market is strategically timed to capitalize on the industry's growth potential
The emergence of new infections in India is a growing concern
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
India Business grew by 11.9% YoY to Rs. 1196.2 crore
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity
Subscribe To Our Newsletter & Stay Updated
